AU2002359851A1 - Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them - Google Patents

Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them

Info

Publication number
AU2002359851A1
AU2002359851A1 AU2002359851A AU2002359851A AU2002359851A1 AU 2002359851 A1 AU2002359851 A1 AU 2002359851A1 AU 2002359851 A AU2002359851 A AU 2002359851A AU 2002359851 A AU2002359851 A AU 2002359851A AU 2002359851 A1 AU2002359851 A1 AU 2002359851A1
Authority
AU
Australia
Prior art keywords
making
methods
variable domains
immunoglobulin variable
canine immunoglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002359851A
Other languages
English (en)
Other versions
AU2002359851A8 (en
Inventor
Ashok Aiyappa
Hongliang Guo
Eugene Regis Krah Iii
Robert Lawton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idexx Laboratories Inc
Original Assignee
Idexx Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idexx Laboratories Inc filed Critical Idexx Laboratories Inc
Publication of AU2002359851A1 publication Critical patent/AU2002359851A1/en
Publication of AU2002359851A8 publication Critical patent/AU2002359851A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2002359851A 2001-12-21 2002-12-20 Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them Abandoned AU2002359851A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34487401P 2001-12-21 2001-12-21
US60/344,874 2001-12-21
PCT/US2002/041362 WO2003060080A2 (en) 2001-12-21 2002-12-20 Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them

Publications (2)

Publication Number Publication Date
AU2002359851A1 true AU2002359851A1 (en) 2003-07-30
AU2002359851A8 AU2002359851A8 (en) 2003-07-30

Family

ID=23352425

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002359851A Abandoned AU2002359851A1 (en) 2001-12-21 2002-12-20 Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them

Country Status (6)

Country Link
US (1) US7261890B2 (https=)
EP (1) EP1485126A4 (https=)
JP (1) JP2005514063A (https=)
AU (1) AU2002359851A1 (https=)
CA (1) CA2469833C (https=)
WO (1) WO2003060080A2 (https=)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
CA2635599C (en) * 2006-01-13 2014-06-17 Irm Llc Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases
NZ584514A (en) 2007-10-19 2012-07-27 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
BRPI0910513B8 (pt) * 2008-07-10 2021-05-25 Toray Industries uso de pelo menos um polipeptídeo, método para a detecção de câncer de mama e leucemia in vitro, e reagente para a detecção de câncer de mama e leucemia
US10611835B2 (en) 2008-07-10 2020-04-07 Toray Industries, Inc. Pharmaceutical composition for treatment and prevention of cancer
EP2331579B1 (en) * 2008-09-04 2017-07-05 Vet Therapeutics, Inc. Monoclonal antibodies
AU2014200771B2 (en) * 2008-09-04 2016-05-26 Vet Therapeutics, Inc. Monoclonal antibodies
EP2411050A4 (en) * 2009-03-25 2013-07-17 Vet Therapeutics Inc ANTIBODY REGIONS WITH A CONSTANT DOMAIN AND THEIR USE
WO2010117448A2 (en) * 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof
WO2010128372A1 (en) 2009-05-08 2010-11-11 Allergosystem S.R.L. A device for protecting pets from allergy
EP2542258A4 (en) * 2010-03-04 2013-08-21 Vet Therapeutics Inc ON CD52 MONOCLONAL ANTIBODIES
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US9616120B2 (en) * 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
WO2011109108A1 (en) * 2010-03-04 2011-09-09 Vet Therapeutics Inc. Monoclonal antibodies directed to cd20
EP2542256B1 (en) 2010-03-04 2019-05-22 MacroGenics, Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
CA2799540A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
WO2012024650A2 (en) * 2010-08-19 2012-02-23 Abbott Laboratories Anti-ngf antibodies and their use
GB2504887B (en) 2011-05-06 2016-02-03 Nvip Pty Ltd Anti-Nerve growth factor antibodies and methods of preparing and using the same
GB2505352B (en) * 2011-05-06 2016-01-27 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
CA2835094C (en) * 2011-05-06 2020-12-22 David Gearing Anti-nerve growth factor antibodies and methods of preparing and using the same
GB201114858D0 (en) 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
SI3498732T1 (sl) * 2011-05-06 2022-04-29 Zoetis Services Llc Protitelesa proti živčnemu rastnemu faktorju ter postopki za pripravo in uporabo le-teh
US9580496B2 (en) 2011-05-06 2017-02-28 Nexvet Australia Pty Ltd Therapeutic canine immunoglobulins and methods of using same
EP2723380B1 (en) 2011-06-24 2019-08-21 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
WO2013054127A1 (en) * 2011-10-13 2013-04-18 Nvip Pty Ltd Canine/feline cd20 binding epitope and compositions for binding thereto
WO2013119419A1 (en) 2012-02-08 2013-08-15 North Carolina State University Treatment of allergic diseases with recombinant antibodies
CA2875783C (en) 2012-06-06 2018-12-11 Zoetis Llc Caninized anti-ngf antibodies and methods thereof
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
CN106029697B (zh) 2013-12-20 2021-06-04 英特维特国际股份有限公司 具有经修饰的ch2-ch3序列的犬抗体
SG11201701128YA (en) 2014-09-12 2017-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
US9758575B2 (en) 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
US11116795B2 (en) 2015-07-10 2021-09-14 The Trustees Of The University Of Pennsylvania Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
CA3005696A1 (en) * 2015-12-18 2017-06-22 Intervet International B.V. Caninized human antibodies to human and canine il-4r alpha
GEP20227398B (en) 2016-04-15 2022-07-25 Macrogenics Inc Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof
WO2018089335A1 (en) 2016-11-09 2018-05-17 North Carolina State University Treatment of allergic diseases with chimeric protein
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
GB2561352B (en) * 2017-04-10 2023-01-18 Genome Res Ltd Animal models and therapeutic molecules
BR112020017701A2 (pt) 2018-03-12 2020-12-29 Zoetis Services Llc Anticorpos anti-ngf e métodos dos mesmos
US11433139B2 (en) 2018-03-16 2022-09-06 Zoetis Services Llc Peptide vaccines against interleukin-31
CA3093539A1 (en) 2018-03-16 2019-09-19 Zoetis Services Llc Interleukin-31 monoclonal antibodies for veterinary use
US12060437B2 (en) 2018-03-23 2024-08-13 North Carolina State University Methods and compositions for antibody to high affinity receptor for IgE
GB2578867A (en) * 2018-10-09 2020-06-03 Genome Res Ltd Animal models and therapeutic molecules
SG11202105153RA (en) 2018-11-19 2021-06-29 Biocytogen Pharmaceuticals Beijing Co Ltd Anti-pd-1 antibodies and uses thereof
WO2020176871A1 (en) * 2019-02-28 2020-09-03 Ann And Robert H. Lurie Children's Hospital Of Chicago Kawasaki disease antibodies identify hepacivirus peptides
CA3145345A1 (en) 2019-07-15 2021-01-21 Intervet International B.V. Caninized antibodies against canine ctla-4
WO2021009188A1 (en) * 2019-07-15 2021-01-21 Intervet International B.V. Caninized antibodies to human and canine ctla-4
BR112022002771A2 (pt) * 2019-08-29 2022-08-09 Kindred Biosciences Inc Anticorpos anti-il31 para uso veterinário
US20220119513A1 (en) 2020-06-08 2022-04-21 Zoetis Services Llc Anti-tgfb antibodies and therapeutic uses thereof
MX2023004020A (es) 2020-10-07 2023-07-07 Zoetis Services Llc Anticuerpos anti-ngf y métodos para su uso.
CA3216131A1 (en) * 2021-04-21 2022-10-27 Nicola J. MASON Canine monoclonal antibodies against canine cytotoxic t lymphocyte associated protein 4 (ctla-4)
CA3232382A1 (en) 2021-09-27 2023-03-30 Zoetis Services Llc Anti- tgf.beta.1,2,3 antibodies and therapeutic uses thereof
WO2025245516A1 (en) * 2024-05-24 2025-11-27 Invetx, Inc. Anti-actrii antibodies and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU640397B2 (en) 1989-08-25 1993-08-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulin
JP2811096B2 (ja) 1989-09-30 1998-10-15 財団法人化学及血清療法研究所 イヌ免疫グロブリンκ鎖の定常領域をコードする遺伝子断片およびマウス×イヌキメラ抗体
JP2837240B2 (ja) 1990-06-07 1998-12-14 財団法人化学及血清療法研究所 イヌ免疫グロブリンγ鎖の定常領域をコードする遺伝子断片およびマウス×イヌキメラ抗体
JP2811089B2 (ja) 1989-08-25 1998-10-15 財団法人化学及血清療法研究所 イヌ×マウスヘテロハイブリドーマおよびイヌ免疫グロブリンλ鎖の定常領域をコードする遺伝子断片
US5330883A (en) 1992-06-29 1994-07-19 Lsi Logic Corporation Techniques for uniformizing photoresist thickness and critical dimension of underlying features
US5622842A (en) 1994-11-09 1997-04-22 Merck & Co., Inc. DNA encoding canine immunoglobulin A
WO1997020859A1 (en) * 1995-12-08 1997-06-12 Idexx Laboratories, Inc. Methods and compositions concerning allergy in dogs
JPH09169795A (ja) 1995-12-22 1997-06-30 Hitachi Chem Co Ltd イヌ免疫グロブリンｅペプチド断片、それをコードするｄｎａ、そのｄｎａを含む組換えベクター、その組換えベクターを含む形質転換体及び抗イヌ免疫グロブリンｅ抗体の製造法
US6504013B1 (en) * 2000-02-01 2003-01-07 Idexx Laboratories, Inc. Canine allergy therapeutic recombinant chimeric anti-IgE monoclonal antibody
DE69922873T2 (de) * 1998-04-09 2005-12-29 Idexx Laboratories, Inc. Spezifische Bindungsproteine zur Behandlung von Allergien beim Hund
US6703360B2 (en) * 2000-04-07 2004-03-09 Heska Corporation Compositions and methods related to canine IgG and canine IL-13 receptors

Also Published As

Publication number Publication date
WO2003060080A3 (en) 2004-02-12
WO2003060080A2 (en) 2003-07-24
US20040181039A1 (en) 2004-09-16
EP1485126A4 (en) 2007-03-21
US7261890B2 (en) 2007-08-28
EP1485126A2 (en) 2004-12-15
AU2002359851A8 (en) 2003-07-30
CA2469833A1 (en) 2003-07-24
CA2469833C (en) 2008-05-20
JP2005514063A (ja) 2005-05-19

Similar Documents

Publication Publication Date Title
AU2002359851A1 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
AU2002251562A1 (en) Anti-CD40 monoclonal antibody
AU2001268855A1 (en) Single-domain antigen-binding antibody fragments derived from llama antibodies
AU2002256895A1 (en) Anti-TRAIL-R antibodies
IL161968A0 (en) Anti-il-6 antibodies, compositions, methods and uses
HUP0302376A3 (en) Anti-tnf antibodies, compositions, methods and uses
AU2002220843A1 (en) Humanised antibodies and uses thereof
AU2002251913A1 (en) Hybrid antibodies and uses thereof
AU1462300A (en) Human pan-hcv human monoclonal antibodies
IL206832A0 (en) Antibodies binding an 161p2f10b epitope and uses thereof
AU2002314825A1 (en) Anti-p40 immunoglobulin derived proteins, compositions, methods and uses
AU2002354929A1 (en) Antibodies specific for nanotubes and related methods and compositions
EP1881064A3 (en) HCV-Anti-core monoclonal antibodies
EP1436329A4 (en) ANTI-PDGF ANTIBODIES AND METHODS FOR PRODUCING FOCUSED ANTIBODIES
EP1581096A3 (en) Antigen pipa and antibodies that bind thereto
AU2002359495A1 (en) Anti-tnf antibodies, compositions, methods and uses
AU2003260513A1 (en) Polyclonal antibodies, preparation method thereof and use of same
HUP0103152A3 (en) Monoclonal antibodies directed against the g3bp protein, and uses
AU2003225976A1 (en) Anti-tnf antibodies, compositions, methods and uses
AU2002365269A1 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
AU2002217212A1 (en) Method for preparing a human monoclonal antibody, fragments thereof or antibodies comprising such fragments, resulting antibodies and use thereof
AU2002306748A1 (en) Anti-gpe antibodies, their uses, and analytical methods for gpe
AU2003237332A1 (en) Anti-relp fusion antibodies, compositions, methods and uses
AU2003244237A1 (en) Monoclonal antibody against adiponectin, preparation method and use thereof
AU2002316619A1 (en) Antimicrobial nucleic acid antibodies, and materials and methods for making and using same

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase